Weight loss pill Wegovy approved by UK medicines regulator
The UK medicines regulator approved a weight loss pill (Wegovy) for private prescription, making it available in pharmacies but not on the NHS. Concerns about counterfeit versions have been raised.
The Full Story
A plain summary built from the channels that reported this story.
The UK medicines regulator has approved a new weight loss pill, Wegovy, for private prescription. From today, adults with a private prescription can buy the once-daily tablets from high street and online pharmacies. The pill is not currently available on the NHS.
The medication contains semaglutide, the same active ingredient as the popular weight loss injections, but in a tablet form. It works by mimicking a natural hormone that suppresses appetite. Unlike the injections, the pills do not need to be stored in a fridge. They are approved for people with a body mass index (BMI) of 30 or above, or a BMI of at least 27 if they also have a weight-related health condition.
Pharmacies are bracing for a surge in demand. One pharmacist said many patients have already been inquiring, either wanting to switch from the injections or start on the pill because it is easier to take. The pharmacist stressed that the medication is heavily regulated and carries risks, including headaches, nausea, diarrhoea, constipation, and more serious but less common side effects such as eye problems and inflammation of the pancreas. Patients must have a face-to-face consultation with a healthcare professional before being prescribed the drug.
The chief executive of Novo Nordisk, the Danish pharmaceutical company that makes Wegovy, described the UK's obesity problem as a "ticking bomb" and said 16 million adults in the UK are living with obesity. He said the pill gives patients more options but warned that it is not cheaper to produce than the injections, so the price for customers will be similar. He also acknowledged concerns about misuse, particularly by people with eating disorders or those seeking cosmetic weight loss, and said the company is focusing on education. On the risk of counterfeit versions, he said Novo Nordisk is partnering with authorities and law enforcement to tackle the black market.
Health experts welcomed the new option but stressed that pills alone are not a solution. They called for broader changes to the food environment to make it easier for people to maintain a healthy weight. Several other pharmaceutical companies are also developing weight loss pills, signalling a growing global market for treatments that address obesity, a condition affecting more than a billion people worldwide.
On screen
Stills are sampled automatically at 60-second intervals. Where shown, the still is the nearest available frame from the relevant broadcast segment and is included to show what was on screen during that part of the broadcast. A still may not correspond to the exact second of a quoted phrase.
Key Claims
Claims reported during this story's coverage, mapped by channel. Ordered by how many channels carried each claim.
| Claim | Channel 5 | BBC One | ITV |
|---|---|---|---|
| The pill is available only via private prescription, not on the NHS. | |||
| The pill is approved for people with a BMI of 30 or higher, or a BMI of at least 27 with a weight-related condition. | · | ||
| Counterfeit versions are a concern because pills are easier to fake than injections. | · | · | |
| Novo Nordisk is partnering with authorities and law enforcement to prevent counterfeiting of the pills. | · | · | |
| Novo Nordisk's CEO said producing the pill is not cheaper than producing the injections. | · | · | |
| Side effects include headaches, nausea, diarrhoea, constipation, and more serious risks such as eye problems and pancreatitis. | · | · |
Channel Perspectives
What each channel focused on, with key quotes.
This channel gave a brief, straightforward announcement of the approval, focusing on the practical implications for families and the fact that the pill is not available on the NHS. It did not include any expert interviews or detailed medical context.
- “Families are bracing themselves for a surge in patients as the Wegovi pill becomes available in the UK.”
- “The once-a-day weight loss pill has been given approval by the medicines regulator.”
BBC News at One provided a detailed report with a health correspondent, including patient perspective and expert commentary. It emphasised the medical criteria, side effects, and the need for broader public health measures to prevent obesity. The tone was informative and cautious.
- “Weight loss medication is now available in pill form in the UK. From today, people with private prescriptions for Wigovi can buy tablets from High Street and online pharmacies for about the same price as the injectable version.”
- “The pills are not currently available on the NHS.”
ITV Lunchtime News secured exclusive access to Novo Nordisk's factory in Denmark and an interview with the company's CEO. The coverage highlighted the scale of production, the CEO's view of obesity as a 'ticking bomb', and addressed concerns about cost, misuse, and counterfeiting directly with the manufacturer.
- “The weight loss drug Wegovi will be available in pill form from today via private prescriptions to adults with a BMI of at least 30 or to those who are overweight and have a related health condition.”
- “The current numbers are staggering. 16 million people is not to be belittled. That is a ticking bomb. It has to start getting addressed today.”
This evening bulletin featured a live interview with a pharmacist, focusing on the practical impact on pharmacies and the risks of counterfeit pills. The tone was conversational and consumer-oriented, warning viewers not to treat the drug as a quick fix and stressing the need for professional medical advice.
- “pharmacies are bracing themselves for a surge in patients wanting the new Wegovi pill. The once a day treatment can now be brought from the high street and online chemists.”
- “It's heavily regulated but also it comes with its risks. So it's not just somebody just taking it like that. So it's got to be discussed with a healthcare professional ideally face to face.”
ITV News at Ten repeated the exclusive factory tour and CEO interview from the lunchtime bulletin, but with a more polished, prime-time presentation. It framed the story as a major development in the global race to treat obesity, noting that other companies have pills in the pipeline.
- “weight loss pills as opposed to jabs today became available on private prescription here for the first time. The tablets are taken once a day and are made by the Danish pharmaceutical Novo Nordisk.”
- “The current numbers are staggering. 16 million people is not to be belittled. That is a ticking bomb. It has to start getting addressed today.”
Broadcast Timeline
News broadcasts tracked for this story, in time order.